Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at Taxoprexin (DHA-paclitaxel) for advanced non small cell lung cancer
This trial was looking at a drug called Taxoprexin for non small cell lung cancer that was stage 3B or stage 4.
Doctors sometimes use chemotherapy to treat advanced lung cancer. In this trial, they were looking at a new drug called Taxoprexin. It is made up of a
The aims of the trial were to find out
- How well Taxoprexin worked for advanced non small cell lung cancer
- What the side effects were
Summary of results
The researchers found that Taxoprexin helped some people. But when they compared their results with trials looking at different types of lung cancer chemotherapy, they found that Taxoprexin didn’t work any better than other drugs.
The trial recruited 44 people who had advanced non small cell lung cancer (NSCLC). Everybody taking part had at least one dose of Taxoprexin.
- In 2 people, the cancer got smaller – the researchers call this a
- In 16 people, the cancer stayed the same size – researchers call this
- In 26 people, the cancer continued to grow
The main side effect was a drop in the number of blood cells, causing an increased risk of infection, bruising or bleeding problems. And 5 people had an allergic reaction to the drug.
As Taxoprexin was no better than other drugs for NSCLC, the trial team didn’t think there should be more trials looking at this as a treatment for lung cancer.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (